Our
History
History
-
Sep. 2024
Gracell was honored as the “Best Employer in Greater Suzhou” for the third consecutive year -
Jun. 2024
Gracell deepened its strategic collaboration with BioBAY and planned to further expand the production capacity of cell therapy drugs in SuZhou, China
-
Feb. 2024
Gracell announced the completion of the acquisition by AstraZeneca
-
Dec. 2023
Gracell entered into a definitive agreement to be acquired by AstraZeneca
-
Dec. 2023
Gracell won the "Most Valuable Chinese Company Listed in the U.S. in 2023" Award
-
Nov. 2023
Gracell won the "BioTech Breakthrough Awards: Overall Immunology Solution of the Year"
-
Aug. 2023
Gracell closed ＄150 million private placement financing, led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed, Pivotal Life Sciences, RA Capital Management and TCGX
-
May. 2023
Gracell expanded clinical evaluation from the therapy area of cancer into autoimmune diseases
-
Nov. 2022
Gracell Biotechnologies won 2022 Fierce Life Sciences Innovation Award
-
Dec. 2021
Gracell Biotechnologies was selected for addition to NASDAQ Biotechnology Index
-
Jan. 2021
Gracell completed IPO and NASDAQ listing, raising $240 million in gross proceeds
-
Jan. 2021
Suzhou manufacturing facility received Medical Products Manufacturing Certificate from JSMPA
-
Oct. 2020
Gracell closed series C funding led by Wellington Management Company, OrbiMed, and Morningside Ventures, and participation from Vivo, Temasek, LAV, Kington Capital, and Chengdu Miaoji
-
Aug. 2020
Gracell opened Suzhou GMP manufacturing facility
-
Feb. 2019
Gracell closed series B funding from Temasek, OrbiMed, Lilly Asia Ventures, Kington Capital, and Chengdu Miaoji
-
Nov. 2017
Gracell's next-day autologous CAR-T cell manufacturing platform was firstly introduced
-
Oct. 2017
Gracell opened Shanghai R&D facility
-
May. 2017
Gracell Biotechnologies was founded by Dr. William Wei Cao and co-founding team